Model-Based Drug-Development (MBDD) - WorldPharma 2010

ePAPER READ

DOWNLOAD ePAPER

worldpharma2010.org

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

Morbid Obesity: BPD-DS & GBPBPD-DS:Bilio-Pancreatic Diversion withDuodenal SwitchGBP:Gastric By-Pass (GBP)

Pharmacological considerations of drug teratogenicity Ã¢Â€Â“ why animal ...

The role of Formyl peptide receptor 2 (Fpr2) in leukocytes trafficking

Allosteric Modulators of mGluRs for Treatment of CNS Disorders

New approaches to fill the methods gap in pharmacovigilance

Copenhagen, Denmark 190710 Antithrombotic treatment in patients

Prediction of individual antibiotic dose in the clinic - WorldPharma ...

Morbid Obesity: BPD-DS & GBPBPD-DS:Bilio-Pancreatic Diversion withDuodenal SwitchGBP:Gastric By-Pass (GBP)

Can We Predict PK in Disease?Yes we can. However, 3 essential elements arerequired for systems and drug independently:1- Data&2- Better Data&3- More Good Data

Page 4: Model-based Drug Development (MBDD)
Page 8 and 9: The Need for Systems ApproachClinic
Page 10 and 11: Separating Systems & Drug Informati
Page 12 and 13: Building Virtual Man vs Populations
Page 14 and 15: Incidence per 100,000% of controlGF
Page 18 and 19: Is that enough?Sometimes not; hence
Page 20 and 21: Highly Non-Linear Systems: OF250200
Page 22: Correspondence for full set of slid

Model-Based Drug-Development (MBDD) - WorldPharma 2010

Create successful ePaper yourself

Delete template?

Save as template?